The Biosecurity Modernization and Innovation Act (H.R. 10197) is a proposed law introduced on August 31, 2026, by Representative August Pfluger (R-TX) and co-sponsored by Representative Chrissy Houlahan (D-PA). The bill aims to enhance the security of nucleic acid synthesis—a process used to create DNA and RNA sequences—by establishing federal requirements for companies involved in this field. Specifically, it mandates that these companies verify the identity and intent of their customers, screen orders for sequences that could pose security risks, refuse sales when necessary, report suspicious activities to the Department of Commerce, undergo regular independent compliance checks, and maintain records for at least five years. The Secretary of Commerce is tasked with providing guidance, maintaining a list of high-risk sequences, and enforcing compliance through inspections and potential civil penalties. The bill also preempts state laws in this area, except for those related to liability, consumer protection, data privacy, public health, and state procurement. The requirements would take effect one year after the bill becomes law.
The Nuclear Threat Initiative (NTI), a nonprofit organization focused on reducing global threats from nuclear, biological, and chemical weapons, has endorsed the Biosecurity Modernization and Innovation Act. NTI highlights the bill's potential to strengthen biosecurity policies, modernize oversight, and foster collaboration among government, industry, and academia. They emphasize that the legislation could embed biosecurity into the foundation of America's growing bioeconomy, ensuring that scientific and technological progress enhances national and global security. NTI also notes that the bill aligns with their recommendations for congressional action to close gaps in U.S. biotechnology oversight.
As of now, there is limited publicly available information detailing specific opposition to the Biosecurity Modernization and Innovation Act. However, potential concerns may arise from smaller biotechnology companies and academic researchers who could find the compliance requirements—such as customer verification, sequence screening, and independent audits—burdensome and costly. These entities might argue that the regulations could stifle innovation, create barriers to market entry, and disproportionately affect smaller players in the industry. Additionally, there may be apprehension about federal preemption of state laws, with critics suggesting that it could undermine state authority in areas like consumer protection and public health.
The analysis of H.R. 10197 reveals no direct industry overlaps between the bill's subject matter and the sponsor August Pfluger's top donor industries. Pfluger has received significant contributions from health professionals totaling $120 million and from retired individuals amounting to $37.5 million. However, these contributions do not directly correlate with the biosecurity and innovation aspects of the bill, which focuses on enhancing the nation's biosecurity infrastructure and advancing research in this area. As such, there is minimal risk of conflict of interest arising from these donor relationships, given the absence of relevant industry ties to the bill's objectives. Voters should be aware that while large donations can raise questions about influence, in this case, the lack of overlap suggests that the bill may be driven more by public health needs than donor interests.
Top industries funding August Pfluger, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
